• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Mission Bio Lands $70M to Expand Cancer Therapies With Single-Cell Multi-Omics Platform

by Jasmine Pennic 08/13/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Mission Bio Lands $70M to Expand Cancer Therapies With Single-Cell Multi-Omics Platform

What You Should Know:

– Mission Bio raises $70 million in Series C funding led by Novo Growth to accelerate the development of cancer therapies with single-cell multi-omics.

– Mission Bio’s Tapestri Platform, the first single-cell platform capable of detecting DNA and protein changes simultaneously, gives a profound insight into the mutations that drive disease to accelerate the development of novel treatments and save patient lives. 


Mission Bio, Inc., a South San Francisco, CA-based pioneer in high-throughput single-cell DNA and multi-omic analysis, today announced $70 million in its Series C financing led by Novo Growth. Soleus Capital also joins the round, along with earlier investors Mayfield, Cota, and Agilent, bringing the company’s total funding to more than $110 million.


Lack of Understanding at the Single-Cell Level

Cancer is a disease of single cells, and it is driven by DNA mutations. Until now, we’ve been using outdated tech that’s misled us to focus on the wrong parts of these cancer cells. Due to this, our current understanding of the disease at the single-cell level has been incomplete.

Only 3% of cancer drugs tested in clinical trials between 2000 and 2015 have been approved to treat patients, and even those that have been approved are not as effective as we’d hope. Even those aimed at specific biomarkers like DNA mutations aren’t effective in every patient with that mutation, resulting in high rates of relapse. Ultimately, the complexity of disease evolution and therapy response requires comprehensive tools to characterize how DNA mutations drive disease at the cellular level, including functional changes in the protein. To develop durable therapies, we require a deeper understanding of all analytes of the cell.


One Platform. Genotype + Phenotype

Founded in 2014, Mission Bio Is the first and only single-cell multi-omics platform developed to accelerate the discovery, development, and delivery of treatments for cancer. The Tapestri Platform is the first-ever single-cell multi-omics platform capable of detecting DNA and protein changes simultaneously from the same cell — a capability necessary for the development of impactful precision therapies.

The award-winning technology has been adopted by Agios, LabCorp, Onconova Therapeutics, and other companies to optimize clinical trials and improve the likelihood of success. Leading cancer centers, including Stanford, MD Anderson Cancer Center, the University of California at San Francisco, and Memorial Sloan Kettering Cancer Center, have leveraged the Tapestri Platform to support their work in therapeutic resistance and treatment response monitoring.

Over the past year, Mission Bio has advanced its efforts to support drug development through clinical trials and the translation of research into novel biomarkers with its growing install base in NCI cancer centers and key biopharma companies.


Expansion Plans

To support Mission Bio’s rapid growth, the funds will scale its single-cell multi-omics technology, the Tapestri® Platform, to expand the company’s reach in more effective clinical trials for novel cancer treatments, along with expanding in cell and gene therapy.

“We’re on a mission to help our customers eliminate cancer. With access to multiple layers of the cellular profile, the Tapestri Platform can help identify novel biomarkers in diseased cells, monitor therapy resistance and response, and accelerate novel therapies through clinical trials,” said Charlie Silver, CEO, and Founder of Mission Bio. “We are delighted to partner with Novo Growth to advance our impact in drug development and cell and gene therapy.”


  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Biomarkers, cancer, Clinical Trials, COTA, dna, gene therapy, LabCorp, MD, MD Anderson, SAN FRANCISCO

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |